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Abstract
Aims/hypothesis Type 1 and type 2 diabetes differ with respect to pathophysiological factors such as beta cell function, insulin
resistance and phenotypic appearance, but there may be overlap between the two forms of diabetes. However, there are relatively
few prospective studies that have characterised the relationship between autoimmunity and incident diabetes. We investigated
associations of antibodies against the 65 kDa isoform of GAD (GAD65) with type 1 diabetes and type 2 diabetes genetic risk
scores and incident diabetes in adults in European Prospective Investigation into Cancer and Nutrition (EPIC)-InterAct, a case-
cohort study nested in the EPIC cohort.
Methods GAD65 antibodies were analysed in EPIC participants (over 40 years of age and free of known diabetes at baseline) by
radioligand binding assay in a random subcohort (n = 15,802) and in incident diabetes cases (n = 11,981). Type 1 diabetes and
type 2 diabetes genetic risk scores were calculated. Associations between GAD65 antibodies and incident diabetes were esti-
mated using Prentice-weighted Cox regression.
Results GAD65 antibody positivity at baseline was associated with development of diabetes during a median follow-up
time of 10.9 years (HR for GAD65 antibody positive vs negative 1.78; 95% CI 1.43, 2.20) after adjustment for sex,
centre, physical activity, smoking status and education. The genetic risk score for type 1 diabetes but not type 2 diabetes
was associated with GAD65 antibody positivity in both the subcohort (OR per SD genetic risk 1.24; 95% CI 1.03, 1.50)
and incident cases (OR 1.97; 95% CI 1.72, 2.26) after adjusting for age and sex. The risk of incident diabetes in those in
the top tertile of the type 1 diabetes genetic risk score who were also GAD65 antibody positive was 3.23 (95% CI 2.10,
4.97) compared with all other individuals, suggesting that 1.8% of incident diabetes in adults was attributable to this
combination of risk factors.
Conclusions/interpretation Our study indicates that incident diabetes in adults has an element of autoimmune aetiology. Thus,
there might be a reason to re-evaluate the present subclassification of diabetes in adulthood.
Keywords Autoantibody . Autoimmunity . Genetic risk score . Incident diabetes . Type 1 diabetes . Type 2 diabetes
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Introduction
Diabetes mellitus has classically been thought to have two
major aetiological subtypes: type 1 diabetes, which is
characterised by autoimmune destruction of beta cells with
subsequent insulin deficiency, and type 2 diabetes, which is
associated with insulin resistance and a relative insulin secreto-
ry deficit [1]. In type 1 diabetes the autoimmune response mani-
fests itself in Tcell reactivity and autoantibody responses direct-
ed against at least four beta cell autoantigens, including the
65 kDa isoform of GAD (GAD65) [2]. Although the pathogen-
esis of type 2 diabetes is thought to be different from that of type
1 diabetes, there may be some overlap; however, the evidence
for this is limited [3]. Associations of beta cell autoimmunity, as
assessed by presence of GAD65 antibodies, with insulin
requirement and diabetes complications have been investigated
in prevalent adult-onset diabetes [4–14]. In contrast, there are
only a few population-based prospective studies exploring the
association between autoimmunity and incident diabetes.
Moreover, while some of these studies reported an association
[15, 16], others have been inconclusive [17–19]. In a recent
meta-analysis Koopman et al reported that the pooled risk esti-
mate of incident type 2 diabetes for GAD65 antibody positivity,
compared with GAD65 antibody negativity, was 3.36 (95% CI
1.9, 5.9) [20]. However, there was significant heterogeneity
between the studies in the meta-analysis.
Susceptibility for development of GAD65 antibody and
type 1 diabetes is at least in part explained by risk alleles
located within the HLA region on chromosome 6 [21–23].
We have previously shown that specific HLA haplotypes are
associated with GAD65 antibody positivity [23]. It is
unknown whether a possible association between GAD65
antibodies and adult-onset diabetes is explained by these
HLA haplotypes. It has also been suggested that type 2 diabe-
tes risk alleles are associated with a subset of adult-onset
diabetes characterised by presence of GAD65 antibodies at
or around the time of diagnosis [24–26], but this association
may be affected by the level of the cut-off used to define
presence of autoantibodies [27].
Thus, we aimed to investigate the association between
GAD65 antibody levels measured using a competition
assay, which increases the precision of the assessment of
autoantibody positivity, and incident adult-onset diabetes
in a large, multi-centre, population-based prospective
study in eight European countries in people who were
over 40 years of age and free of known diabetes at base-
line. In addition, we investigated whether genetic risk
scores (GRSs) for type 1 diabetes and type 2 diabetes
are associated with GAD65 antibody positivity, and the
potential for either of these risk scores to modify the
association of GAD65 antibodies with incident adult-
onset diabetes.
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Methods
Population The design and methods of the European
Prospective Investigation into Cancer and Nutrition (EPIC)-
InterAct case-cohort study have previously been described
[28]. A total of 340,234 EPIC participants, who were over the
age of 40 and free of known diabetes at baseline, in eight of the
ten EPIC study countries (26 centres) were followed up for 3.99
million person-years (median follow-up 10.9 years), during
which 12,403 incident cases of diabetes were ascertained and
verified. Themean (SD) age at diagnosis was 62.3 (7.8) years in
men and 62.6 (8.2) years in women [28]. Ascertainment of
incident diabetes involved multiple sources of evidence includ-
ing self-report, linkage to primary care registers, secondary care
registers, medication use (drug registers), hospital admissions
and mortality data, with a minimum of two data sources being
required to confirm the diagnosis. Cases in Denmark and
Sweden were not ascertained by self-report but identified via
local and national diabetes and pharmaceutical registers, and
hence all ascertained cases were considered to be verified.
Information from any follow-up visit or external evidence with
a date later than the baseline visit was used. Follow-up was
censored at the date of diagnosis, 31 December 2007 or the
date of death, whichever occurred first. A centre-stratified
subcohort of 16,835 (4.9% of the entire EPIC cohort) individ-
uals was selected at random [28]. We excluded 548 individuals
with known prevalent diabetes and 133 with unknown diabetes
status at baseline. We also excluded 422 cases and 352
subcohort participants (of whom 34 were incident cases) with
insufficient sample volume for GAD65 antibody measurement,
resulting in 15,802 subcohort participants and 11,981 incident
cases being included in the analysis.
All study participants gave informed consent, and the
investigation has been carried out in accordance with the
Declaration of Helsinki as revised in 2008.
GAD65 antibody measurement Blood samples were drawn at
the time of participation in EPIC, at which time all participants
were free of known diabetes. Blood plasma was prepared and
stored at −196°C in liquid nitrogen at the coordinating centre
at the International Agency for Research into Cancer (IARC)
in Lyon, France, or in liquid nitrogen in local biorepositories
except for Umeå, where −80°C freezers were used [28].
The samples had been subject to at least two freeze-thaw
cycles before being analysed for GAD65 antibody.
Recombinant [35]S-GAD65 was produced in an in vitro
coupled transcription and translation system with SP6 RNA
polymerase and nuclease-treated rabbit reticulocyte lysate
(Promega, Madison, WI, USA) as previously described [29].
The WHO standard [30] was included and used to express
immunoglobulin binding levels in relative units.
To determine the cut-off for GAD65 antibody positivity,
we used a competition assay employing recombinant human
GAD65 (rhGAD65) (Diamyd Medical, Stockholm, Sweden)
as previously described [31]. A total of 900 serum samples
were randomly selected across countries in the EPIC-InterAct
study population. The samples were incubated with
radiolabelled GAD65 in the absence or presence of
rhGAD65 (200 ng/ml) or BSA (200 ng/ml). Samples in which
binding to radiolabelled GAD65 was reduced by 50% in the
presence of rhGAD65, but not BSA, were considered to be
positive for GAD65-specific antibodies. We used 50% as a
cut-off for successful competition as an approximation of the
IC50. Given the low sample volume, we chose to use the
competitor at the optimal concentration (200 ng/ml) found in
previous experiments, in which we titrated the amount of
rhGAD65 necessary to give maximal competition. In a varia-
tion of the traditional receiver operating characteristic (ROC)
analysis, we plotted GAD65 antibody levels of samples that
were competed by ≥50% against GAD65 antibody levels of
samples that were competed by <50%. The area under the
ROC curve was 0.97, indicating excellent predictive ability
of the GAD65 antibody measurement. At a cut-off level of
≥65 U/ml, the measurement had 99% specificity and 85%
sensitivity (electronic supplementary material [ESM] Fig. 1).
Thereafter, all samples in the subcohort (n = 15,802) and inci-
dent cases (n = 11,981) were analysed for GAD65 antibodies
in a radiobinding assay (RBA) as previously described [29].
Measurement of covariatesWeight, height, and waist and hip
circumferences were measured with participants not wearing
shoes and in light clothing or underwear, as described previ-
ously [28]. BMI was calculated as weight/height squared (kg/
m2). Waist circumference was measured either at the
narrowest circumference of the torso or at the midpoint
between the lower ribs and the iliac crest. Hip circumference
was measured horizontally at the level of the largest lateral
extension of the hips or over the buttocks. Anthropometric
data were mostly self-reported in the Oxford centre, and waist
and hip circumferences were not measured in the Umeå centre
(n = 1845).
Standardised information on highest educational level
(none, primary, technical, secondary or further education)
and smoking status (current smoker, never a smoker or former
smoker) was collected by questionnaire at baseline [28].
Physical activity was assessed using a brief questionnaire
covering occupation and recreational activity, from which a
validated physical activity index (inactive, moderately inac-
tive, moderately active or active) was derived [32].
Genetic analysis and GRS Samples were processed for array-
based genotyping if they had sufficient DNA that could be
successfully genotyped on TaqMan (Thermo Fisher
Scientific, Waltham, MA, USA) or Sequenom (San Diego,
CA, USA) platforms and had sex chromosome genotypes
concordant with self-reported sex. Samples that failed one
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genotyping round for reasons that did not relate to sample
quality (e.g. signal intensity outliers or plates/arrays with an
unusually high failure rate) were repeated. Samples were geno-
typed on the Illumina 660 W-Quad BeadChip, the Illumina
HumanCoreExome-12 or the Illumina HumanCoreExome-24
(San Diego, CA, USA). Samples genotyped on the Illumina
660W-QuadBeadChip were randomly selected from the avail-
able samples with the number of individuals selected per centre
being proportional to the percentage of total cases in that
centre. The Danish samples were not available for genotyping
at this stage. Genotyping was carried out at theWellcome Trust
Sanger Institute. Most of the remaining non-Danish samples
were genotyped on the Illumina HumanCoreExome-12 at
Cambridge Genomic Services in the University of
Cambridge Department of Pathology. Finally, the Danish
samples and repeat samples due to poor genotyping were geno-
typed on the Illumina HumanCoreExome-24 also at
Cambridge Genomic Services. Sample quality control criteria
varied slightly by array but included call rate (<95.4% in
Illumina 660, <98% in core exome arrays), X chromosome
heterozygosity concordance with self-reported sex, outliers
for heterozygosity and concordance with previous genotyping
results.
From the genome-wide array data, we calculated a type 1
diabetes GRS as a weighted average of 33 SNPs, including
five HLA variants. The relevant SNPs and their individual
associations with GAD65 antibody positivity are described
in ESM Table 1 [33]. We also calculated a type 2 diabetes
GRS as a weighted average of 68 SNPs from a DIAbetes
Genetics Replication And Meta-analysis (DIAGRAM)
consortium publication [34].
Statistical analyses Baseline characteristics of the analysis
sample were summarised by GAD65 antibody status (nega-
tive/positive), separately within the subcohort and incident
diabetes cases, using means and standard deviations for contin-
uous variables (except for GAD65 antibody level, which had a
skewed distribution so the median and interquartile range were
used) and percentages for categorical variables.
The association between GAD65 antibody status (positive/
negative) and incident diabetes was estimated using Prentice-
weighted Cox regression, which is appropriate for estimating
association in a case-cohort study. We fitted models within
each country and the estimated HRs were combined across
countries using random effects meta-analysis. We fitted three
models including the following covariates: Model 1—age (as
underlying time scale), sex and centre; Model 2—also includ-
ing physical activity, smoking status and education; Model
3—also including family history of diabetes. In order to study
the effects of high vs low GAD65 antibody levels, GAD65
antibody-positive individuals were further subdivided into
those with GAD65 antibody equal to or above, and those with
GAD65 antibody below, 167.5 U/ml, which is the median
antibody level in the GAD65 antibody-positive group in this
study. Prentice-weighted Cox regression was also used to test
possible multiplicative interactions of GAD65 antibody status
with: (1) sex; (2) BMI category; (3) waist/hip ratio (WHR)
category (sex-specific tertiles); and (4) type 1 diabetes GRS
tertile. The interactions with anthropometry measures were
tested because of prior studies suggesting that adiposity could
moderate the association of autoimmunity with diabetes
[9, 10]. In this instance we fitted models to the overall dataset
with adjustment for country, due to insufficient data within
each country to obtain country-specific estimates. HRs and
95% CIs within each subgroup were calculated.
The associations of the type 1 diabetes GRS and the type 2
diabetes GRSwith GAD65 antibody status (positive/negative)
were estimated separately in the subcohort and the incident
diabetes cases, using logistic regression adjusted for age and
sex, since the prevalence of autoimmunity is associated with
age and sex. Models were fitted within each country and esti-
mated odds ratios combined across countries using random
effects meta-analysis. ORs (and 95% CIs) per risk allele of
each of the individual SNPs contributing to the type 1 diabetes
GRS were also calculated in the subcohort using the same
method.
The association between the type 1 diabetes GRS and inci-
dent diabetes, byGAD65 antibody status, was estimated using
Prentice-weighted Cox regression as described above.
Results
Three hundred and sixteen (2.0%) individuals in the subcohort
and 413 (3.4%) incident cases were GAD65 antibody positive
as defined by having a level of ≥65 U/ml (Table 1).
Individuals who were GAD65 antibody positive in both the
subcohort and incident cases tended to be leaner, and fewer of
these individuals reported a family history of diabetes. There
were no other major differences in baseline characteristics by
GAD65 antibody status (Table 1). The distributions of the
type 1 diabetes GRS and the type 2 diabetes GRS were similar
when comparing individuals who were GAD65 antibody
positive and negative, in both the subcohort and incident
diabetes cases (Table 1, Fig. 1a,b).
GAD65 antibody positivity was associated with a higher
incidence of diabetes (Table 2) consistently across countries
(Fig. 2). Of the potential confounders considered, only family
history of diabetes had an impact on the HR, which increased
from 1.78 (95% CI 1.43, 2.20) in Model 2 to 2.19 (95% CI
1.56, 3.07) in Model 3, which includes family history of
diabetes. Data on family history of diabetes were not collected
at some centres; fitting all three models to the sample with
complete data on all covariates gave results similar to those
above (ESM Table 2), suggesting the presence of negative
confounding by family history. The association was markedly
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stronger in those with high GAD65 antibody levels than in
those with lower levels, relative to those who were GAD65
antibody negative (Table 2), suggesting a potential dose–
response effect. We undertook a sensitivity analysis to exam-
ine the effect of lowering the threshold for defining GAD65
antibody positivity from ≥65 U/ml to ≥40 U/ml. This would
lead to an additional 255 incident diabetes cases being labelled
as GAD65 antibody positive, but led to a weaker overall asso-
ciation between GAD65 antibody positivity and incident
diabetes. A formal comparison of the effect size for the asso-
ciation with incident diabetes for the two definitions of
GAD65 antibody positivity was not significant (p = 0.099).
Type 1 diabetes GRS, but not type 2 diabetes GRS, was
associated with GAD65 antibody positivity in both the
subcohort and incident diabetes cases (Table 3). Of the five
SNPs in the type 1 diabetes GRS that are linked to HLA haplo-
types, three were significantly associated with GAD65 anti-
body positivity in the subcohort after adjusting for age and
sex (ESM Table 2). However, HLA haplotypes did not explain
the association between GAD65 antibodies and incident
diabetes. In a sensitivity analysis restricted to those individuals
with complete relevant data (n = 10,893), the HR for incident
diabetes in those positive for GAD65 antibodies compared with
those individuals who were negative was 2.22 (95% CI 1.49,
3.31) without adjustment and 2.13 (95% CI 1.46, 3.11) with
adjustment for a five HLA haplotype risk score. There was no
association between any individual type 2 diabetes-associated
SNP and GAD65 antibody level (ESM Table 3).
There was no overall association between type 1 diabetes
GRS and incident diabetes (HR 1.02 per SD type 1 diabetes
GRS; 95% CI 0.99, 1.06) when adjusted for age, sex, physical
activity, smoking status, education and BMI. However, there
were significant interactions of GAD65 antibody status with
BMI category (p = 0.001),WHR category (p <0.001) and type
1 diabetes GRS tertile (p <0.001), but no interaction of
GAD65 antibody status with sex, on the hazard of diabetes.
The associations between GAD65 antibody positivity and
incident diabetes were strongest in the lowest categories of
BMI and WHR, and in the highest tertile of type 1 diabetes
GRS (Table 4).
Table 1 Baseline characteristics of the subcohort and incident diabetes cases; the EPIC-InterAct study (N = 27,039)
Characteristic Subcohort Incident diabetes cases
GAD65 antibody− n = 15,486 GAD65 antibody+ n = 316 GAD65 antibody− n = 11,568 GAD65 antibody+ n = 413
Women (%) 62.4 64.6 50.2 58.1
Age (years) 52.3 (9.1) 52.7 (9.3) 55.5 (7.6) 55.0 (8.4)
BMI (kg/m2) 26.0 (4.2) 25.8 (4.2) 29.8 (4.7) 28.4 (5.1)
WHR 0.85 (0.09) 0.85 (0.09) 0.92 (0.09) 0.89 (0.09)
Physical activity
Inactive 23.7 25.2 30.1 33.3
Moderately inactive 33.5 35.8 32.9 28.0
Moderately active 22.7 19.5 20.3 20.2
Active 20.1 19.5 16.7 18.5
Highest schooling level
None 7.7 10.3 10.1 8.6
Primary 33.0 34.3 41.9 40.9
Technical 23.3 20.8 23.6 21.9
Secondary 15.4 14.7 11.1 14.5
Further education 20.7 19.9 13.3 14.0
Smoking status
Never 47.0 50.5 41.0 43.2
Former 27.1 25.2 31.2 28.0
Current 25.9 24.3 27.8 28.8
Family history of diabetes (yes) 18.7 14.5 36.3 29.5
GAD65 antibody (U/ml) 0.0 (0, 0) 133.3 (86.7, 336.1) 0.0 (0,0) 207.1 (99.3, 1000)
Type 1 diabetes risk score 0.6 (0.1) 0.6 (0.1) 0.6 (0.1) 0.6 (0.1)
Type 2 diabetes risk score 70.6 (5.7) 70.4 (5.2) 72.4 (5.7) 71.6 (5.7)
Values are presented as percentages for categorical variables and mean (SD) for continuous variables, except for GAD65 antibody, which has a skewed
distribution and so median (interquartile range) is presented
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Among GAD65 antibody-positive individuals there was a
significant association of the type 1 diabetes GRS with inci-
dent diabetes (HR 2.42 per SD type 1 diabetes GRS; 95%
CI 1.83, 3.21). There was no evidence of an association
among GAD65 antibody-negative individuals (HR 1.00 per
SD type 1 diabetes GRS; 95% CI 0.97, 1.04). In order to
contextualise these interactions, we also analysed the inter-
action in terms of tertiles of the type 1 diabetes GRS rather
than standard deviations. Among the 26,693 individuals
with relevant data, 552 (2.1%) were GAD65 antibody posi-
tive and 284 (1.1%) were GAD65 antibody positive and also
in the top tertile of the type 1 diabetes GRS. Of these 284
individuals, 196 developed incident diabetes and 88 were
non-cases. The HR for incident diabetes in the GAD65
antibody-positive individuals comparing the top tertile of
the type 1 diabetes GRS with the combination of the other
two tertiles was 4.83 (95% CI 2.47, 9.43). When the
exposed group was defined as those who were GAD65 anti-
body positive and in the top tertile of the type 1 diabetes
GRS, the HR for incident diabetes compared with all other
individuals was 3.23 (95% CI 2.10, 4.97). From this it
follows that the population attributable fraction, the theoret-
ical fraction of all cases attributable to having GAD65 anti-
bodies and high type 1 diabetes genetic risk, was 1.8%.
Baseline characteristics of the subcohort stratified by both
GAD65 antibody status and tertile of the type 1 diabetes
GRS (high vs middle/low) are summarised in ESM
Table 4. In a further post hoc analysis, using ≥40 U/ml
rather than ≥65 U/ml as the threshold for antibody positivity,
the HR for incident diabetes comparing those who were
antibody positive and in the top tertile of the type 1 diabetes
GRS was 2.05 (95% CI 1.60, 2.62); the population attribut-
able fraction was 1.7%.
Discussion
This large, prospective, population-based European study
found a significant association between GAD65 antibody
positivity and development of incident diabetes after the age
of 40 years in individuals free of known diabetes at baseline in
eight European countries. A GRS for type 1 diabetes, but not
type 2 diabetes, was associated with GAD65 antibody posi-
tivity. There was no overall association of the type 1 diabetes
GRS with incident diabetes, but, in the subgroup of individ-
uals who were positive for GAD65 antibodies, the type 1
diabetes GRS was strongly associated with incident diabetes.
From these data we estimate that just under 2% of all cases of
adult-onset diabetes are attributable to the combination of
having a high genetic risk for type 1 diabetes and being posi-
tive for GAD65 antibodies.
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Fig. 1 Violin plots of risk scores according to GAD65 antibody status for
(a) type 1 diabetes and (b) type 2 diabetes in the EPIC-InterAct subcohort
and incident diabetes cases. n values in (a) are: 12,526 (subcohort,
GAD65Ab−), 149 (subcohort, low GAD65Ab+), 104 (subcohort, high
GAD65Ab+), 9442 (incident diabetes, GAD65Ab−), 139 (incident diabe-
tes, low GAD65Ab+), and 196 (incident diabetes, high GAD65Ab+). n
values in (b) are: 12,249 (subcohort, GAD65Ab−), 146 (subcohort, low
GAD65Ab+), 99 (subcohort, high GAD65Ab+), 9126 (incident diabetes,
GAD65Ab−) and 135 (incident diabetes, low GAD65Ab+), 192 (incident
diabetes, high GAD65Ab+). ‘High’ GAD65Ab+ is defined as GAD65
antibody ≥167.5 U/ml and ‘low’ GAD65Ab+ is defined as GAD65 anti-
body <167.5 U/ml. GAD65Ab+, GAD65 antibody positive; GAD65Ab−,
GAD65 antibody negative; T1D, type 1 diabetes; T2D, type 2 diabetes
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Our study provides definitive evidence of the association
betweenGAD65 antibodies and incident diabetes in European
populations, by virtue of the size of the population and exten-
sive follow-up (nearly 4 million person-years), as well as the
use of a specific method for defining antibody positivity. An
association between higher GAD65 antibody levels and inci-
dent diabetes in adults has been suggested previously [15, 16].
However, the Botnia study was not population-based and was
based on relatives of individuals with type 2 diabetes [15], and
our previous investigation of adult participants in the
Västerbotten Intervention Programme was extremely small
and produced estimates of the effect size with wide confidence
intervals [16]. A null association between GAD65 antibodies
and development of type 2 diabetes reported in Northern Italy
may reflect the small size of this study, which was underpow-
ered to detect a true association [18]. The Diabetes Prevention
Program also reported no association between GAD65 anti-
bodies and development of type 2 diabetes [19]. However, the
follow-up of the Diabetes Prevention Program cohort was
very short (3.2 years) and included individuals of various
ethnicities with different risks of diabetes, both of which
may explain the null overall association. Finally, Sorgjerd
et al reported that none of the 349 individuals that developed
type 2 diabetes in The Nord-Trøndelag Health Study (HUNT)
3 were positive for GAD65 antibodies in HUNT2 [12].
However, these individuals represented only 23% of all indi-
viduals that developed type 2 diabetes in HUNT3, and type 2
diabetes was classified as absence of GAD65 antibodies.
Notably, we did not analyse the GAD65 antibody status at
time of diagnosis and assume that a significant portion of these
individuals will present GAD65 antibodies at diagnosis.
Finally, development of type 2 diabetes in HUNT3 was
analysed in a retrospective manner, while our study was
conducted prospectively. Therefore, outcomes of these studies
are difficult to compare. Our study was restricted to European
populations, so we cannot shed any light on ethnic differences
in the links between these antibodies and incident diabetes.
Our finding that type 1 diabetes GRS was associated with
GAD65 antibody positivity in the subcohort is in line with the
study by Mishra et al, which was based on prevalent latent
autoimmune diabetes in adults (LADA) cases and non-
diabetic control individuals [27]. The HLA types included in
our analysis were selected on the basis of their known associ-
ation with type 1 diabetes as part of an overall type 1 diabetes
GRS [35]. The association was mainly explained by the SNPs
for HLA-DR3/DR, HLA-DR3/DR4 and HLA-DQB1*0302
(also namedHLA-DQ8).We reported in a preliminary smaller
study [23] that the presence of HLA-DR3 was associated with
GAD65 antibody levels in a non-diabetic population. The
same pattern of association for HLA-DR3 was also observed
in a study of Finnish school children, where, in addition,
HLA-DQB1*0302 was also associated with GAD65 antibody
positivity [21]. However, both of these small studies were
cross-sectional and were unable to examine whether the indi-
viduals with antibodies and type 1 diabetes risk alleles were
more or less likely to develop diabetes later in life.
This study indicates that autoimmunity plays a role in the
aetiology of adult-onset diabetes, irrespective of how the
people were classified clinically. We estimate that 1.8% of
incident diabetes cases in adulthood are attributable to the
combination of having a high genetic risk for type 1 diabetes
and having GAD65 antibodies. Our interpretation is that there
is an overlap in the aetiology in adult diabetes. It has been
shown that presence of GAD65 antibodies predicts future beta
cell dysfunction which could be the result of an autoimmune
attack on the beta cells (reviewed in [3]), even in people clas-
sified as having type 2 diabetes. In some cases, the autoim-
mune attack does not lead to a total beta cell failure. The result
of the autoimmune attack is very dependent on the titres of
autoantibodies, presence of multiple antibodies and genetic
risk [3]. This notion of a scale of the effect of the autoimmune
attack was further strengthened by the finding that transient
GAD65 antibodies [12] led to earlier onset of diabetes and
contributed to a relative beta cell dysfunction. In line with
Table 2 HRs for incident diabetes comparing GAD65 antibody-positive with GAD65 antibody-negative groups; the EPIC-InterAct study
Variable Model 1 Model 2 Model 3
N HR Lower Upper I2 (%) N HR Lower Upper I2 (%) N HR Lower Upper I2 (%)
GAD65 antibody+ vs
GAD65 antibody−
705 (+) 26,334 (−) 1.80 1.48 2.20 34 691 (+)
25,456 (−)
1.78 1.43 2.20 36 351 (+)
12,484 (−)
2.19 1.56 3.07 43
‘High’ GAD65 antibody+
vs GAD65 antibody−
353 (high) 2.46 1.91 3.17 18 341 (high) 2.43 1.85 3.18 19 211 (high) 2.73 1.58 4.70 62
‘Low’ GAD65 antibody+
vs GAD65 antibody−
352 (low) 1.32 1.01 1.72 25 350 (low) 1.28 0.99 1.66 18 140 (low) 1.74 1.21 2.50 3
Model 1: age (as underlying time scale), sex and centre; Model 2: age (as underlying time scale), sex, centre, physical activity, smoking status and
education; Model 3: age (as underlying time scale), sex, centre, physical activity, smoking status, education and family history of diabetes
I2 represents percentage of variability due to heterogeneity between countries. ‘High’ GAD65 antibody+ is defined as GAD65 antibody ≥167.5 U/ml
and ‘low’ GAD65 antibody+ is defined as GAD65 antibody <167.5 U/ml
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our hypothesis that there is an overlap between aetiologies in
adult-onset diabetes, autoimmunity as defined by insulitis
assessed by histological investigation was found in pancreases
of people diagnosed with type 2 diabetes [36]. However, we
can only speculate about the mechanism behind the associa-
tion, although it has been reported that insulin resistance could
be present also among those with GAD65 antibodies [11]. The
mechanism could be that insulin resistance increases the
secretion of insulin from the beta cells, thereby exposing more
antigen (i.e. GAD65, which is co-excreted with insulin from
the vesicles in the beta cells) to the immune system. In people
with a predisposition for autoimmunity, this autoimmune
response towards the beta cells might lead to beta cell
dysfunction and/or beta cell death. This hypothesis is support-
ed by findings in an experimental study design [37] that
reported an association between GAD65 antibodies and a
decrease in maximal insulin secretory capacity in people with-
out diabetes. This suggests that the presence of GAD65 anti-
bodies is a pancreatic marker of a subclinical autoimmune
process that could lead to insulin deficiency and subsequently
type 2 diabetes.
Taken together, there might be a reason to re-evaluate the
present subclassification of diabetes in adulthood [1]. This re-
evaluation might also lead to studies aimed at the prevention
of diabetes, while taking the presence of autoimmunity into
account, and to studies trying to optimise the treatment of
adult-onset diabetes.
Our study has limitations. The presence of GAD65 anti-
body at baseline suggests an autoimmune component in the
aetiology of adult-onset diabetes over the age of 40. We delib-
erately sought to use this descriptive term to avoid forcing
individuals into predetermined diagnostic categories, since
this has the potential to create circular arguments [38, 39].
We did not have access to GAD65 antibody measurements
at the time of diabetes diagnosis but would anticipate that
antibodies measured before the diagnosis of diabetes would
persist, as previous studies have demonstrated [40, 41].
Several features of our study add to the strength of this ana-
lysis. First, all samples were analysed in the same laboratory.
The samples were blinded to case or non-case status and
samples of participants from different countries were analysed
together to minimise assay variation. Second, the cut-off was
determined in a subsample of 900 samples, based on specific-
ity of binding, rather than setting an arbitrary cut-off level
based on percentiles. Third, the same cut-off level was applied
to all samples.
In conclusion, in this large, population-based prospective
study, we found that GAD65 antibody positivity was associ-
ated with the incidence of diabetes after the age of 40 years. A
GRS for type 1 diabetes but not type 2 diabetes was associated
with GAD65 antibody positivity and with the incidence of
diabetes in those who were GAD65 antibody positive. Our
data suggest that incident diabetes in adults includes an
element of autoimmune aetiology, which warrants further
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Fig. 2 HRs for incident diabetes
comparing GAD65 antibody-
positive with GAD65 antibody-
negative groups, by country, in
the EPIC-InterAct study (Model
2, n = 26,147)
Table 3 Associations of type 1 diabetes and type 2 diabetes GRSs with GAD65 antibody positivity in the subcohort and incident diabetes cases; the
EPIC-InterAct study
Variable Subcohort Incident diabetes cases
N OR Lower Upper I2 (%) N OR Lower Upper I2 (%)
Type 1 diabetes GRS (per 1 SD) 12,779 1.24 1.03 1.50 46 9777 1.97 1.72 2.26 12
Type 2 diabetes GRS (per 1 SD) 11,054 0.97 0.85 1.12 0 8228 0.85 0.76 0.96 0
Associations are estimated from logistic regression, adjusted for age and sex. Models fit within each country; estimates combined across countries using
random effects meta-analysis
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prospective studies into the risk factors associated. Moreover,
future studies with a different design should investigate the
implications of this finding for subclassification of incident
diabetes in adults, selection of primary treatment modalities
and frequency of risk factor assessment to enhance prognosis.
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Table 4 HRs (95% CIs) for inci-
dent diabetes comparing GAD65
antibody-positive with GAD65
antibody-negative groups within
categories of BMI, WHR (sex-
specific tertiles) and tertiles of
type 1 diabetes GRS; the EPIC-
InterAct study
Variable GAD65 antibody+ vs GAD65 antibody−
n HR 95% CI
BMI (kg/m2)
<25 8251 3.35 (2.51, 4.47)
25 to <30 10,742 1.48 (1.14, 1.93)
≥30 6983 1.46 (1.02, 2.08)
WHR
<0.91 (men), <0.77 (women) 5170 2.91 (2.00, 4.24)
0.91 to <0. 96 (men), 0.77 to <0.82 (women) 6770 2.37 (1.69, 3.30)
≥0.96 (men), ≥0.82 (women) 12,364 1.33 (1.05, 1.69)
Type 1 diabetes GRS
<0.56 6939 1.25 (0.85, 1.84)
0.56 to <0.62 7066 1.14 (0.81, 1.60)
≥0.62 7258 2.52 (1.94, 3.29)
Models adjusted for age (as underlying timescale), sex, country, physical activity, smoking status and education.
Tertiles calculated using distributions in the subcohort
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